Search Results for ""
- ACP Online (7461)
- Annals of Internal Medicine (6915)
- ACP Store (240)
- IM Matters (3160)
- ACP Hospitalist (2455)
- Annals of Internal Medicine: Clinical Cases (499)
Displaying 781 - 790 of 7461 in ACP Online
ACP MKSAP Tracker | Residency Progress Tracking & Reporting Tool
Track resident performance and assignments with ACP MKSAP Tracker. Built-in reporting, progress monitoring, and program-level insights for educators.
ACP MKSAP Learning Objectives and CME/MOC/CPD
Learning Objectives The learning objectives of ACP MKSAP are as follows:
ACP MKSAP - Frequently Asked Questions
Access and FunctionalityHow do I access my ACP MKSAP subscription?Log in to your ACP MKSAP account here. ACP MKSAP shares the same username and password as ACP Online, Annals of Internal Medicine, and most other online products from ACP. If you created a username and password when you purchased ACP MKSAP or if you are an ACP member and already have an ACP Online username and password, your username and password are the credentials you should enter to access ACP MKSAP.
ACP MKSAP CORE
The American College of Physicians (ACP) has launched a new Medical Knowledge Self-Assessment (ACP MKSAP®) feature, Confirmation of Relevant Education (CORE), to support internal medicine physicians in demonstrating their continuous learning.
ACP MKSAP Copyright and Restrictions
ACP MKSAP is a package that includes a feature-rich online application and a collection of mobile apps that enable you to work offline and later sync your answers. The online application includes the entirety of content, launching with nearly 2,000 multiple-choice questions and updated information on hundreds of topics in the field of internal medicine, organized into subspecialty sections, with content refreshes and new questions added regularly. ACP MKSAP is a state-of-the-art learning system, enabling learners to have unprecedented control and unparalleled ease of use.
Buy ACP MKSAP | Internal Medicine Board Review & Question Bank
Purchase ACP MKSAP and access thousands of board-style questions, personalized learning tools, and ABIM-aligned content. 1- and 3-year options available.
List of Sessions - Hospital Med 100
Over 100 hours of high-yield recorded sessions Order Now Alphabetical by Title A New Era in Sickle Cell Disease Speaker: Chancellor Donald, MD
ACP Hospital Med 100
ACP Hospital Med 100 is no longer available to purchase. If you have already purchased ACP Hospital Med 100, access your sessions here.
List of Sessions - ACP CME 175
Over 175 hours of high-yield recorded sessions Order ACP CME 175
ACP CME 170
ACP's Internal Medicine Meeting 2022 was held in April but the CME 170 is here for those who could not attend the live meeting & for Premium Access registrants.
Displaying 781 - 790 of 6915 in Annals of Internal Medicine
These Annals of Internal Medicine results only contain recent articles.
- Visit annals.org to search all content back to 1927.
- View Annals of Internal Medicine CME by topic here.
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19: A Target Trial Emulation Study: Annals of Internal Medicine: Vol 176, No 4
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is uncertain. Objective: To examine the real-world effectiveness of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with COVID-19 during the Omicron outbreak. Design: Target trial emulation study. Setting: Electronic health databases in Hong Kong. Participants: The molnupiravir emulated trial included hospitalized patients with COVID-19 aged 18 years or older between 26 February and 18 July 2022 (n = 16 495). The nirmatrelvir–ritonavir emulated trial included hospitalized patients with COVID-19 aged 18 years or older between 16 March and 18 July 2022 (n = 7119). Intervention: Initiation of molnupiravir or nirmatrelvir–ritonavir within 5 days of hospitalization with COVID-19 versus no initiation of molnupiravir or nirmatrelvir–ritonavir. Measurements: Effectiveness against all-cause mortality, intensive care unit (ICU) admission, or use of ventilatory support within 28 days. Results: The use of oral antivirals in hospitalized patients with COVID-19 was associated with a lower risk for all-cause mortality (molnupiravir: hazard ratio [HR], 0.87 [95% CI, 0.81 to 0.93]; nirmatrelvir–ritonavir: HR, 0.77 [CI, 0.66 to 0.90]) but no significant risk reduction in terms of ICU admission (molnupiravir: HR, 1.02 [CI, 0.76 to 1.36]; nirmatrelvir–ritonavir: HR, 1.08 [CI, 0.58 to 2.02]) or the need for ventilatory support (molnupiravir: HR, 1.07 [CI, 0.89 to 1.30]; nirmatrelvir–ritonavir: HR, 1.03 [CI, 0.70 to 1.52]). There was no significant interaction between drug treatment and the number of COVID-19 vaccine doses received, thereby supporting the effectiveness of oral antivirals regardless of vaccination status. No significant interaction between nirmatrelvir–ritonavir treatment and age, sex, or Charlson Comorbidity Index was observed, whereas molnupiravir tended to be more effective in older people. Limitation: The outcome of ICU admission or need for ventilatory support may not capture all severe COVID-19 cases; unmeasured confounders, such as obesity and health behaviors, may exist. Conclusion: Molnupiravir and nirmatrelvir–ritonavir reduced all-cause mortality in both vaccinated and unvaccinated hospitalized patients. No significant reduction in ICU admission or the need for ventilatory support was observed. Primary Funding Source: Health and Medical Research Fund Research on COVID-19, Government of the Hong Kong Special Administrative Region; Research Grants Council, Collaborative Research Fund; and Health Bureau, Government of the Hong Kong Special Administrative Region.